Myo-inositol has a strong safety profile across a wide range of doses and populations. The FDA classifies it as Generally Recognized As Safe (GRAS), permitting its use in food and even infant formula with no specific dosage limitations beyond standard manufacturing practices. Clinical trials have tested doses as high as 18 grams per day for three months and 4 grams per day for a full year without significant adverse effects.
Side Effects and Dose Thresholds
At the doses found in most supplements (typically 2 to 4 grams per day), myo-inositol causes few if any side effects. Problems tend to show up at 12 grams per day or higher, and even then they’re mild: nausea, gas, diarrhea, difficulty sleeping, headache, dizziness, and tiredness. These gastrointestinal symptoms are the most commonly reported issue across clinical trials, and they resolve when the dose is reduced.
Clinical trials testing doses ranging from 4 to 60 grams per day over periods of one to twelve months consistently report that the only adverse events are those mild gut symptoms at the higher end. No toxicity to the kidneys, no cognitive effects, and no cancer risk have been identified in preclinical research.
Standard Dosing for Common Uses
Most people take myo-inositol for polycystic ovary syndrome (PCOS), insulin resistance, or metabolic health. The typical dose in these studies is 4 grams per day, split into two doses of 2 grams each. Many PCOS-focused supplements combine myo-inositol with D-chiro-inositol in a 40:1 ratio, which mirrors the natural balance of these two forms in the body. This combination has been used in clinical trials for six months with no relevant side effects recorded.
Safety During Pregnancy
Myo-inositol has been studied specifically in pregnant women, primarily for preventing gestational diabetes. In these trials, it did not increase the risk of preterm delivery, cesarean section, abnormally large babies, neonatal low blood sugar, or NICU admission compared to placebo. In fact, supplementation was associated with reduced rates of gestational diabetes (11% vs. 25% in the placebo group), lower risk of preterm birth, and fewer cases of excessive birth weight.
The transfer of myo-inositol across the placenta to the fetus does not appear to be clinically significant. That said, long-term data across diverse populations is still limited, so if you’re pregnant or planning to become pregnant, it’s worth discussing supplementation with your provider in the context of your specific risk factors.
Use in Adolescents
Myo-inositol has been tested in teenagers as young as 13 with PCOS. In a study of adolescent girls aged 13 to 19, a dose of 4 grams per day for three months was described as safe and effective for addressing the metabolic disruptions associated with PCOS. No notable adverse effects were reported in this age group.
Interactions With Medications
If you take metformin or other blood sugar-lowering medications, myo-inositol is worth paying attention to. Research shows it can amplify metformin’s effects. In one study, women who had been taking 2 grams of myo-inositol daily before starting metformin experienced a more pronounced drop in blood sugar, insulin resistance markers, and certain hormone levels compared to women taking metformin alone.
Importantly, this amplification appeared to target only overactive cells rather than disrupting normal function. Researchers found no signs of the combination pushing healthy hormone levels too low or causing drug-induced problems with pituitary function. Still, if you’re on metformin or insulin, your prescriber should know you’re taking myo-inositol so they can monitor your blood sugar appropriately.
Myo-inositol has also been shown to enhance the effects of selenomethionine on thyroid hormones in people with autoimmune thyroid conditions. If you’re being treated for a thyroid disorder, this is another reason to mention inositol use to whoever manages your thyroid care.
Long-Term Use
The longest controlled safety data available covers 12 months at 4 grams per day, with no concerning findings. Beyond formal trials, myo-inositol has been used in research settings for decades in people with insulin resistance and PCOS. No pattern of cumulative toxicity or delayed adverse effects has emerged over that time. While multi-year randomized trial data doesn’t exist, the combination of its GRAS status, its natural presence in the body and in foods like fruits, beans, and grains, and decades of clinical use provides a reassuring picture for ongoing supplementation at standard doses.